Is There a Real Consensus on Pyrilutamide? Community Skepticism, Cost, and Combo Trials

Pyrilutamide (KX-826) is the topical androgen receptor antagonist that was supposed to be the cleaner, better-tolerated successor to RU58841 — and the community is, to put it gently, unconvinced. The Phase III readouts in China underwhelmed, the cost per gram is brutal, and the people who actually need it (fin/dut non-responders, AAS users trying to firewall scalp DHT) are split between cautious adopters and outright skeptics. This is a state-of-the-stack writeup: what the evidence and the field reports actually say, where pyril seems to earn its slot, and what the alternatives look like.

Where the data actually sits#

Pyrilutamide's pitch is mechanistic: a topical AR antagonist with poor systemic absorption, in theory giving RU58841-style local androgen blockade without RU's sketchy pharmacokinetic profile and unknown long-term safety. The problem is the clinical signal hasn't matched the marketing.

• The Kintor Phase III in male AGA missed its primary endpoint on TAHC (target area hair count) versus vehicle at the headline timepoint. Secondary endpoints were mixed.
• Earlier Phase II data had looked more promising, which set expectations the Phase III didn't meet.
• There is no published head-to-head against finasteride, dutasteride, or RU58841. Every "pyril vs RU" claim circulating is anecdotal.
• Systemic absorption appears low in the published PK work, which is the main reason it stays interesting despite the efficacy questions.

The practical read: pyrilutamide is a real AR antagonist, it does something on scalp, but the magnitude of effect in a controlled trial is smaller than the hype implied. That is the entire reason the tressless consensus thread reads the way it does.

What the community is actually reporting#

Reading across the long-running tressless and MESO threads, a few patterns repeat:

• Fin/dut responders adding pyril report modest incremental density, hard to distinguish from microneedling cadence or minoxidil dose changes happening at the same time.
• Fin/dut non-responders or sides-quitters are the most interesting cohort. A non-trivial minority describe meaningful regrowth on pyril monotherapy or pyril + minoxidil after oral 5-AR inhibitors did nothing or had to be dropped.
• RU58841 veterans switching to pyril are the most disappointed group. The common report is that pyril feels weaker than RU at equivalent application volumes, and several users cycle back to RU after 6-9 months.
• Shed timelines are reported around weeks 4-10, similar to other AR-active interventions, with stabilization typically claimed by month 4-6 in responders.

"Users express skepticism due to failed trials and high costs, with some waiting for more data before trying pyrilutamide." — tressless consensus thread

That quote is the honest center of gravity right now. Pyril is not a flop, but it is not the finasteride-killer the early Phase II buzz suggested either.

Dosing and combinations that pull ahead#

The protocols that show up most often in field reports cluster around the Kintor trial concentration and a handful of stacking patterns. None of these are clinician-endorsed; they are what the community runs.

Variable	Common community range	Notes
Concentration	0.5% solution	Matches the trial arm; higher concentrations are reported but evidence is thin
Frequency	Twice daily	BID dosing is the trial protocol; QD is reported as underwhelming
Volume	~1 mL/day total scalp	Cost scales hard with volume, which is the real-world ceiling
Vehicle	Ethanol/PG base	Same family as RU and topical fin vehicles

Stacking patterns the community reports as most productive:

• Pyril + oral or topical minoxidil + microneedling 1x/week at 1.0-1.5 mm. This is the default modern stack, and it's the one most success reports are built on.
• Pyril layered on top of low-dose oral finasteride (0.25-1 mg/day) or dutasteride (0.5 mg 2-3x/week) for users who tolerate 5-AR inhibition systemically but want extra local AR blockade — particularly relevant for anyone running AAS, where scalp DHT and direct AR activation from the compound itself are both in play.
• Pyril as the AR-blockade layer when oral 5-AR inhibitors are off the table (sides, fertility window, personal preference). This is the cohort where pyril arguably earns its price.

What consistently doesn't pull ahead: pyril monotherapy without minoxidil, without microneedling, and without addressing the underlying DHT picture. As a single agent it is not strong enough to carry a stack on its own.

The cost problem is the adoption problem#

Pyrilutamide raw is expensive, and finished 0.5% solutions from compounding sources land well above what topical fin or even RU58841 cost on a per-month basis. For a compound whose Phase III missed its primary endpoint, that price tag is the single biggest reason the community keeps stalling on it. A user willing to spend that monthly budget can instead run:

• Oral dutasteride + topical minoxidil + microneedling, which has the strongest evidence base of any retention stack.
• Topical finasteride + oral minoxidil + microneedling, for users avoiding systemic 5-AR inhibition.
• RU58841 + minoxidil + microneedling, accepting RU's unknown long-term safety in exchange for stronger anecdotal AR blockade and a fraction of pyril's cost.

Pyril's slot is narrow: the user who has failed or rejected oral 5-AR inhibitors, wants a topical AR antagonist, and is unwilling to run RU. That is a real cohort — just a small one.

Clascoterone and what's next#

Clascoterone (Breezula in the AGA indication, Winlevi for acne) is the agent the community is increasingly watching as the more credible topical AR antagonist. The acne formulation is FDA-approved, the AGA Phase III program has been running, and the metabolism-to-cortexolone profile is genuinely attractive for a topical. Early scalp data and the off-label use of Winlevi on the hairline are the most-discussed alternatives in the same threads where pyril skepticism lives.

For users deciding right now:

• If the goal is a topical AR antagonist today, pyril and RU are the two real options, with pyril winning on safety profile and RU winning on cost and reported potency.
• If waiting 12-24 months is acceptable, clascoterone's AGA readouts and pricing will likely reshape this entire tier.
• Oral 5-AR inhibition plus minoxidil plus microneedling remains the highest-evidence backbone regardless of which AR antagonist gets layered on top.

Bottom line#

There is no clean consensus on pyrilutamide because the data doesn't support one. It is a legitimate topical AR antagonist with a clean systemic profile, a disappointing Phase III, a real but modest field-report signal, and a price that makes sense only for a specific user — the fin/dut non-responder or sides-quitter who won't run RU. Layered onto minoxidil and microneedling it can earn its slot. As a standalone or as a fin replacement for someone who tolerates fin fine, it doesn't. Watch the clascoterone readouts; that is where this category is going.